Trans-septal mitral valve-in-valve replacement can be successfully performed in patients with degenerated mitral bioprostheses and severely reduced LVEF.
Answers are grounded in this paper and cite their sources.
Supports TMViV feasibility in low-LVEF mitral bioprosthesis degeneration; hypothesis-generating and should not yet change practice.
We present hereby the case of a 75-year-old woman with a degenerated mitral bioprosthesis and severely reduced left ventricular ejection fraction who underwent a successful trans-septal mitral valve-in-valve (TMViV) replacement using a 29mm Edwards Sapien S3 transcatheter heart valve. We also performed a literature review.
No takes yet. Share an insight, caveat, or question.
Perrin et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: